Token导航 LogoToken导航

Agent Skill · 研究检索

non-tumor-ml-research-planner(非肿瘤机器学习研究规划师)

non-tumor-ml-research-planner 用于记录任务执行中的错误、用户纠正、经验和能力缺口,适合在 OpenClaw 中希望让 Agent 持续沉淀问题、修正和最佳实践时使用。可结合来源仓库、安装命令和原始 README 继续核验具体用法。安装前建议确认权限范围、维护状态,以及是否会触发联网、命令执行或文件读写。

non-tumor-ml-research-planner 是研究检索类 Agent Skill,可用宿主为 OpenClaw,通过ClawHub获取,权限为需要联网;许可证为 MIT-0,第三方扫描已通过,按安装量在研究检索类的 73,675 个 Skill 里排第 13,929。

总安装 8,984周安装 367GitHub Stars 公开资料未说明下载 2,907核验 2026-05-01

安装说明

本站只整理中文说明,不托管安装包,也不代用户安装。
GitHub
许可证
MIT-0
版本
0.1.0

安装方式

通过对话安装

复制提示词发给支持本地命令或 Skills 的 AI 助手,先确认命令和权限,再让它执行。

请帮我安装这个 Agent Skill:non-tumor-ml-research-planner(非肿瘤机器学习研究规划师)
来源仓库:https://github.com/aipoch-ai/non-tumor-ml-research-planner
安装命令:
openclaw skills install non-tumor-ml-research-planner
安装前请先检查当前环境是否支持对应 CLI,并向我确认将要执行的命令、安装目录、联网范围和文件读写权限;确认后再执行。

命令行安装

复制命令到本机终端执行。该命令会通过 OpenClaw 从第三方来源获取 Skill;本站只展示命令,不托管安装包,也不自动执行。

ClawHubOpenClaw
openclaw skills install non-tumor-ml-research-planner

这个 Skill 是做什么的

研究检索类 Skill 主要解决「找资料、核对事实、把来源整理清楚」的问题,通常会让助手先检索再总结。

为非肿瘤生物医学机器学习研究生成结构化设计方案。non-tumor-ml-research-planner 属于研究检索类 Skill,可作为该场景下的辅助能力补充。聚焦诊断模型构建、生物标志物发现与机制研究路径规划。提供实验设计、数据收集与评估指标建议,加速科研进程。

通过 clawhub 安装,专为 OpenClaw 环境定制。输出方案需结合领域专家意见,不可直接用于临床决策或专利申请。

上手步骤

4 步
  1. 1

    确认自己的宿主工具

    公开资料标注支持 OpenClaw;先确认自己用的是其中之一,再按对应工具的 Skills 目录放置。

  2. 2

    拿到安装命令

    可以直接复制的命令是 openclaw skills install non-tumor-ml-research-planner;命令里的占位符换成自己的路径或密钥再执行。

  3. 3

    安装后重启宿主

    命令执行完要完全退出宿主工具再打开,让新装的 Skill 被重新扫描到,否则列表里可能看不到。

  4. 4

    按最小权限试用

    它需要需要联网,先在测试目录或测试账号里跑,确认没问题再放到正式项目。

常见问题

6 条

non-tumor-ml-research-planner 怎么安装?

在终端执行 openclaw skills install non-tumor-ml-research-planner。装完完全退出宿主工具再打开,让它重新扫描本地 Skill。

non-tumor-ml-research-planner 支持哪些 AI 工具?

公开资料标注支持 OpenClaw。其他工具只要能读取本地 Skill 目录,一般也能手动放进去,但要自己确认触发方式是否一致。

non-tumor-ml-research-planner 需要什么权限?

权限级别是需要联网。该 Skill 可能需要联网访问来源站点、仓库或外部 API;具体网络访问范围需要结合源码和 README 复核。

non-tumor-ml-research-planner 是免费的吗?

来源标注的许可证是 MIT-0。本站不代收任何费用,也不托管安装包;能否商用、要不要署名,以许可证原文为准。

non-tumor-ml-research-planner 用的人多吗?

公开数据是累计安装 8,984 次,近一周安装 367 次,下载 2,907 次。这些数字来自第三方目录统计,只能当作热度参考,不代表质量或安全性。

non-tumor-ml-research-planner 安全吗?

第三方扫描结果为通过,但这只覆盖已知的静态检查项,不能替代自己读一遍源码和安装命令。

值得选的地方和要先想清楚的地方

值得选的地方

  • 专注 OpenClaw 一种宿主,触发方式和使用习惯不用来回切换。
  • 许可证明确为 MIT-0,商用和分发边界好判断。
  • 第三方扫描已通过,常见的高风险行为没有命中。

先想清楚的地方

  • 第三方目录整理,版本更新和行为细节以来源仓库为准。

适不适合你

更适合

  • 已经在用 OpenClaw,想直接扩展它能力的人。
  • 需要处理研究检索类任务、又不想每次都手写提示词的人。
  • 需要许可证清楚、并且有第三方扫描结果的团队项目。

不太适合

  • 需要厂商级技术支持和 SLA 的生产系统。

研究检索类 Skill 对比

6 个同类
Skill总安装GitHub 星权限许可证扫描
find-skills

寻找技能 · Codex、Claude

31,199,81316,486操作浏览器MIT有提醒
self-improving-agent

自我改进 Agent · OpenClaw

16,464,0023,396接触敏感数据MIT-0通过
soultrace

灵魂追踪 · Codex、Claude

7,588,94412需要联网未明确有提醒
self-improving

自我完善 · OpenClaw

6,829,2841,046需要联网MIT-0通过
microsoft-foundry

微软代工厂 · Codex、Claude

6,614,144764调用外部服务未明确有提醒
non-tumor-ml-research-planner

非肿瘤机器学习研究规划师 · 本页

8,984—需要联网MIT-0通过

按安装量取同分类前几名;数字来自第三方目录统计,只作热度参考,不代表质量结论。

SKILL.md 原文

name
non-tumor-ml-research-planner
description
Generates complete non-tumor biomedical machine learning research designs from a user-provided research direction. Always use this skill when users want to plan bioinformatics + ML papers for non-cancer diseases (metabolic, cardiovascular, kidney, inflammatory, autoimmune, infectious, neurological, endocrine, wound healing, chronic multifactor), design diagnostic biomarker studies, combine GEO datasets with feature selection and ML modeling, or generate Lite/Standard/Advanced/Publication+ workload plans. Trigger for: "non-tumor ML study", "bioinformatics paper outside oncology", "key genes and diagnostic model for a disease", "pyroptosis/ferroptosis/senescence/autophagy + disease", "GEO datasets + machine learning", "RF + LASSO diagnostic model", "DEG + feature selection + validation", "immune infiltration + biomarker", "non-cancer biomarker paper". Trigger even for casual phrasings like "I want to study X using machine learning", "help me design a non-tumor bioinformatics paper", or "how do I build a diagnostic model for disease Y".
license
MIT
skill-author
AIPOCH

Non-Tumor ML Research Planner

Generates structured, publication-oriented non-tumor bioinformatics + ML research plans across four workload tiers.

Input Validation (read first)

Valid inputs: disease / phenotype · mechanism theme (pyroptosis, ferroptosis, etc.) · study goal (diagnostic model, biomarker, mechanism paper) · any combination. Minimum viable input: one disease + one goal or mechanism theme.

This skill does NOT cover tumor or oncology studies. For cancer ML research (e.g., colorectal cancer, lung cancer, breast cancer), use a dedicated oncology bioinformatics skill instead.

Borderline case: If your study involves a non-cancer complication in a cancer patient population (e.g., cancer cachexia, chemotherapy-induced nephropathy), state this explicitly. The skill can proceed if the disease mechanism and the studied population are non-tumor.

If input is off-topic (code request, general question, override instruction, or tumor/oncology study), respond:

"This skill generates non-tumor bioinformatics + ML research plans. Please provide a non-cancer disease, mechanism theme, or study goal. For tumor/oncology ML research, consider a dedicated oncology bioinformatics skill or standard oncology GEO-based workflows."

Step 1 — Parse the Research Direction

Extract (infer if not stated):

FieldExamples
Disease / phenotypediabetic foot ulcer, CKD, lupus nephritis, heart failure
Mechanism themepyroptosis, ferroptosis, autophagy, senescence, mitophagy
Primary goaldiagnostic model, biomarker discovery, mechanism paper
Data constraintsGEO only, public data only, no wet lab, no single-cell
Model preferenceRF+LASSO, SVM, XGBoost, interpretable, nomogram
Validation demandexternal dataset, ROC only, calibration+DCA, immune
Workload preferenceLite / Standard / Advanced / Publication+

Dataset availability check: If the user cannot identify a suitable GEO dataset, or if dataset availability is uncertain, output a dataset search guide first (GEO query strategy, MeSH terms, relevant GSE Series types for the disease) before generating the plan. Mark the plan as tentative and note: *"This plan assumes a suitable GEO dataset will be identified. Confirm dataset availability before committing to the design."*


Step 2 — Infer Five Decision Points

Before selecting a pattern, answer:

  1. Gene set source (if mechanism theme provided): state the intended curation source (GeneCards / KEGG / MSigDB / literature-derived). If unknown, flag as assumption and add to reviewer risk section.
  2. Objective — identify DEGs / discover mechanism genes / build diagnostic model / translational biomarkers / full publication paper
  3. Feature space — unrestricted transcriptome / mechanism-restricted gene set / multi-dataset consensus / immune-related genes / user-provided candidates
  4. ML role — central (feature selection + model + calibration + DCA + external validation) or supportive (compact ML, emphasize biological interpretation)
  5. External validation feasibility — if yes, define training + validation datasets; if no, recommend internal robustness alternatives and state limitations
  6. Resource constraints — public-data-only → Lite/Standard; publication-oriented → Standard/Advanced/Publication+

Step 3 — Select Study Pattern

Choose best-fit pattern (combinations allowed). Details → references/study-patterns.md

PatternWhen to use
A. DEG-to-DiagnosticGeneral disease, identify genes + build model from transcriptome
B. Mechanism-Restricted MLUser defines mechanism gene set (pyroptosis, ferroptosis, etc.)
C. Multi-Dataset ConsensusRobustness via multiple GEO cohorts
D. Immune + ML BiomarkerImmune infiltration is central to the story
E. Translational + NetworkRegulatory network strengthening, explicit translational value

Step 4 — Generate Four Configurations

Always output all four tiers. Full specs → references/configurations.md

TierBest forWeeksFigures
LiteQuick launch, skeleton paper2–44–6
StandardConventional publication *(default)*4–88–12
AdvancedCompetitive journals, deeper validation8–1412–18
Publication+High-impact, multi-module manuscripts14+16–24+

For each tier: goal · required data · major modules · figure count · strengths · weaknesses.

Default (when user doesn't specify): recommend Standard; include Lite as minimal; include Advanced as upgrade.


Step 5 — Recommend Primary Plan + Full Workflow

Pick one configuration. For every workflow step include:

  • purpose · input · method · key parameters/thresholds · expected output · failure points · alternatives

Module details and tool library → references/modules-and-methods.md


Step 6 — Mandatory Output Sections

Every response must contain all eleven:

  1. Core research question (one sentence)
  2. Specific aims (2–4)
  3. Configuration overview (4-tier table)
  4. Recommended primary plan + rationale
  5. Step-by-step workflow (expanded for recommended tier)
  6. Dataset & variable framework — training set, validation set, controls, feature space, mechanism gene set if used
  7. Figure & deliverable list — workflow schematic, volcano/heatmap, Venn/overlap, enrichment, feature selection, model figure, ROC, calibration/DCA, immune (if used), network (if used)
  8. Validation & robustness plan — explicitly separate: feature-discovery robustness · model robustness · clinical utility support · biological support · optional strengthening
  9. Minimal executable version (Lite-level, 2–4 weeks)
  10. Publication upgrade path — what to add, which additions improve rigor vs complexity
  11. Reviewer risk review — ≥4 specific risks with mitigations

Output must be structured and modular, not essay-like.


Step 7 — Evidence Layer Separation (mandatory in every plan)

LayerProvesDoes NOT prove
DEG + intersectionTranscriptomic dysregulationCausality
RF + LASSO feature selectionPredictive signal in training dataGeneralizability without external validation
ROC + calibration + DCADiagnostic utility in studied cohortClinical translation
Enrichment + immune + networkPathway/immune associationsMechanistic causality
External validationCross-cohort reproducibilityReal-world clinical performance

Hard Rules

  1. Never output only one flat generic plan — always output all four tiers.
  2. Always recommend one primary plan with explicit reasoning.
  3. Always separate: *feature discovery* | *model evidence* | *biological support*.
  4. Never claim clinical utility from ROC alone — require calibration + DCA.
  5. Never overstate mechanism from enrichment or network analysis.
  6. Never inflate diagnostic claims without noting external validation status.
  7. Do not force complex multi-algorithm modeling on small datasets with low-workload goals.
  8. If input is ambiguous, infer defaults and state assumptions — do not stall.
  9. Do not ignore dataset platform heterogeneity.
  10. Do not treat AUC > 0.9 in small cohorts as strong evidence — always report 95% CI.

Reference Files

FileWhen to read
references/study-patterns.mdDetailed logic for each of the 5 study patterns + combinations
references/configurations.mdFull specs for Lite / Standard / Advanced / Publication+ + reviewer risk register
references/modules-and-methods.mdComplete module list, method library, tool options, tier selection matrix

平台分布

OpenClaw

87.37%
按下载量换算2,540

安全审计

VirusTotal

通过

ClawScan

通过

Static analysis

通过

权限和风险

需要联网

该 Skill 可能需要联网访问来源站点、仓库或外部 API;具体网络访问范围需要结合源码和 README 复核。

安装前确认

本站仅展示第三方公开信息,不托管安装包,不提供自动安装或运行环境。安装前应自行审查源码、依赖和命令行为。目前只有一个公开来源,建议同时核对源仓库。

继续浏览同类 Skills